Medicare AdvantageCoverageMedium impact
MA07.003f, Photodynamic Therapy Using Verteporfin (Visudyne®)
Independence Blue Cross·Ophthalmology, Dermatology, Oncology·Pharmacy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA07.003f for Photodynamic Therapy Using Verteporfin (Visudyne®) has been reissued with an effective date of March 4, 2026. This is a pharmacy-related policy update that may affect coverage or billing requirements for this specific photodynamic therapy treatment.
Action Required
By March 4, 2026: Billing team should review the complete policy MA07.003f for Photodynamic Therapy Using Verteporfin (Visudyne®) to identify any changes in coverage criteria, prior authorization requirements, or billing guidelines. Update billing procedures and provider documentation requirements as specified in the full policy text.